In line with such results, here we evidenced that with the exception of NPM1 and NCL, which have been ruled out as major targets for the peptide [31,34], none of the other CIGB-300-interacting CK2 substrates were identified as down-phosphorylated in AML cells. The gene discussed is NPM1; the disease is acute myeloid leukemia.